Menu

HHS Overrules FDA on Plan B

Despite scientific evidence that Plan B emergency contraception is safe for women of all ages, the department of Health and Human Services declined to approve it for over-the-counter use.

Dec 10, 2011
Tia Ghose

FLICKR, VIXYVIEW

After the department of Health and Human Services (HHS) overruled the Food and Drug Administration (FDA) on Wednesday regarding the approval of emergency contraceptive Plan B, many are wondering whether politics, not science, guided the decision. The department ruled to keep existing restrictions on Plan B, which currently cannot be sold without a prescription to those younger than 17, despite the FDA’s conclusion that the drug was safe and effective for fertile women of all ages and should be available over-the-counter.

As a rationale for keeping the restrictions in place, HHS head Kathleen Sebelius said that about 10 percent of women as young as 11 are physically capable of getting pregnant but may lack the cognitive and behavioral development to use Plan B properly.

But many question the scientific merits of the decision. FDA director Margaret Hamburg released a statement in response reiterating that the scientific evidence suggests Plan B is “is safe and effective and should be approved for nonprescription use for all females of child-bearing potential," ScienceInsider reported. The FDA Office of Women’s Health head Susan Wood previously stated that much riskier drugs, such as acetaminophen (Tylenol), are routinely available over-the-counter. “One of the president’s first executive orders was that we will use science to guide decisions and not politics,” one White House official told The Washington Post.  “And I don’t understand how this can possibly square with science.”

The pill is no stranger to controversy. The FDA was accused during the Bush administration of bowing to conservative politics by resisting all over-the-counter use for the drug.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.